Cytokinetically quiescent (G0/G1) human multiple myeloma cells are susceptible to simultaneous inhibition of Chk1 and MEK1/2

Blood

Volumn 118, Issue 19, 2011, Pages 5189-5200

  Pei, Xin Yan ^a   Dai, Yun ^a   Youssefian, Leena E ^a   Chen, Shuang ^a   Bodie, Wesley W ^a   Takabatake, Yukie ^a   Felthousen, Jessica ^a   Almenara, Jorge A ^a   Kramer, Lora B ^a   Dent, Paul ^b   Grant, Steven ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CD34 ANTIGEN; CHECKPOINT KINASE 1; ETOPOSIDE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PACLITAXEL; PYRONINE; SELUMETINIB; SHORT HAIRPIN RNA; SYNDECAN 1; 3 (CARBAMOYLAMINO) 5 (3 FLUOROPHENYL) N (3 PIPERIDYL)THIOPHENE 2 CARBOXAMIDE; 3-(CARBAMOYLAMINO)-5-(3-FLUOROPHENYL)-N-(3-PIPERIDYL)THIOPHENE-2-CARBOXAMIDE; BENZIMIDAZOLE DERIVATIVE; DRUG DERIVATIVE; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; PROTEIN KINASE; PROTEIN KINASE INHIBITOR; SDC1 PROTEIN, HUMAN; THIOPHENE DERIVATIVE; UREA;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL KINETICS; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME LOCALIZATION; GENE SILENCING; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE TEST; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SIDE POPULATION CELL; STAINING; UPREGULATION; DNA DAMAGE; DRUG ANTAGONISM; DRUG EFFECT; METABOLISM; PATHOLOGY; TUMOR CELL LINE;

APOPTOSIS; BENZIMIDAZOLES; CELL LINE, TUMOR; DNA DAMAGE; G0 PHASE; G1 PHASE; HUMANS; INTERLEUKIN-6; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MULTIPLE MYELOMA; PROTEIN KINASE INHIBITORS; PROTEIN KINASES; SYNDECAN-1; THIOPHENES; UREA;

EID: 81055147625     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-02-339432     Document Type: Article

References (50)

1. Drewinko B, Alexanian R, Boyer H, Barlogie B, Rubinow SI. The growth fraction of human myeloma cells. Blood. 1981;57(2):333-338. (Pubitemid 11174896)
2. Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet. 1999;113(1):73-77. (Pubitemid 29354098)
3. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer. 2002;2(3):175-187. (Pubitemid 37328787)
4. Kondoh E, Mori S, Yamaguchi K, et al. Targeting slow-proliferating ovarian cancer cells. Int J Cancer. 2010;126(10):2448-2456.
5. Dimanche-Boitrel MT, Pelletier H, Genne P, et al. Confluence-dependent resistance in human colon cancer cells: role of reduced drug accumulation and low intrinsic chemosensitivity of resting cells. Int J Cancer. 1992;50(5):677-682.
6. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol. 2007;19(2):238-245. (Pubitemid 46386406)
7. Kastan MB, Bartek J. Cell-cycle checkpoints and cancer. Nature. 2004;432(7015):316-323. (Pubitemid 39551659)
8. Niida H, Nakanishi M. DNA damage checkpoints in mammals. Mutagenesis. 2006;21(1):3-9. (Pubitemid 43288730)
9. Paulsen RD, Cimprich KA. The ATR pathway: fine-tuning the fork. DNA Repair (Amst). 2007;6(7):953-966. (Pubitemid 46880476)
10. Bartek J, Lukas J. Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell. 2003;3(5):421-429. (Pubitemid 38340288)
11. Marini F, Nardo T, Giannattasio M, et al. DNA nucleotide excision repair-dependent signaling to checkpoint activation. Proc Natl Acad Sci U S A. 2006;103(46):17325-17330. (Pubitemid 44788968)
12. Vogel C, Hager C, Bastians H. Mechanisms of mitotic cell death induced by chemotherapy-mediated G2 checkpoint abrogation. Cancer Res. 2007;67(1):339-345. (Pubitemid 46142793)
13. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer. 2007;7(4):295-308. (Pubitemid 46480970)
14. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene. 2007;26(22):3291-3310. (Pubitemid 46763022)
15. Allen LF, Sebolt-Leopold J, Meyer MB. CI-1040 (PD184352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol. 2003;30(5 suppl 16):105-116. (Pubitemid 37433401)
16. Yeh TC, Marsh V, Bernat BA, et al. Biological characterization of ARRY-142886 (AZD6244), a potent, highly selective mitogen-activated protein kinase kinase 1/2 inhibitor. Clin Cancer Res. 2007;13(5):1576-1583. (Pubitemid 46450450)
17. Tai YT, Fulciniti M, Hideshima T, et al. Targeting MEK induces myeloma cell cytotoxicity and inhibits osteoclastogenesis. Blood. 2007;110(5):1656-1663. (Pubitemid 47443984)
18. Dai Y, Yu C, Singh V, et al. Pharmacological inhibitors of the mitogen-activated protein kinase (MAPK) kinase/MAPK cascade interact synergistically with UCN-01 to induce mitochondrial dysfunction and apoptosis in human leukemia cells. Cancer Res. 2001;61(13):5106-5115. (Pubitemid 32681542)
19. Dai Y, Landowski TH, Rosen ST, Dent P, Grant S. Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and -resistant myeloma cells through an IL-6-independent mechanism. Blood. 2002;100(9):3333-3343. (Pubitemid 35217085)
20. Pei XY, Dai Y, Tenorio S, et al. MEK1/2 inhibitors potentiate UCN-01 lethality in human multiple myeloma cells through a Bim-dependent mechanism. Blood. 2007;110(6):2092-2101. (Pubitemid 47443927)
21. Dai Y, Chen S, Pei XY, et al. Interruption of the Ras/MEK/ERK signaling cascade enhances Chk1 inhibitor-induced DNA damage in vitro and in vivo in human multiple myeloma cells. Blood. 2008;112(6):2439-2449.
22. Zabludoff SD, Deng C, Grondine MR, et al. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies. Mol Cancer Ther. 2008;7(9):2955-2966.
23. Syljuåsen RG, Sorensen CS, Hansen LT, et al. Inhibition of human Chk1 causes increased initiation of DNA replication, phosphorylation of ATR targets, and DNA breakage. Mol Cell Biol. 2005;25(9):3553-3562. (Pubitemid 40559562)
24. Vasudevan S, Tong Y, Steitz JA. Switching from repression to activation: microRNAs can upregulate translation. Science. 2007;318(5858):1931-1934.
25. Dai Y, Chen S, Venditti CA, et al. Vorinostat synergistically potentiates MK-0457 lethality in chronic myelogenous leukemia cells sensitive and resistant to imatinib mesylate. Blood. 2008;112(3):793-804.
26. Pham NA, Jacobberger JW, Schimmer AD et al. The dietary isothiocyanate sulforaphane targets pathways of apoptosis, cell cycle arrest, and oxidative stress in human pancreatic cancer cells and inhibits tumor growth in severe combined immunodeficient mice. Mol Cancer Ther. 2004;3(10):1239-1248. (Pubitemid 39440169)
27. Pellicciari C, Mangiarotti R, Bottone MG, Danova M, Wang E. Identification of resting cells by dual-parameter flow cytometry of statin expression and DNA content. Cytometry. 1995;21(4):329-337.
28. Shen H, Boyer M, Cheng T. Flow cytometry-based cell cycle measurement of mouse hematopoietic stem and progenitor cells. Methods Mol Biol. 2008;430(II):77-86.
29. Ladd AC, Pyatt R, Gothot A, et al. Orderly process of sequential cytokine stimulation is required for activation and maximal proliferation of primitive human bone marrow CD34+ hematopoietic progenitor cells residing in G0. Blood. 1997;90(2):658-668. (Pubitemid 27299106)
30. Goodell MA, McKinney-Freeman S, Camargo FD. Isolation and characterization of side population cells. Methods Mol Biol. 2005;290:343-352.
31. Jakubikova J, Adamia S, Kost-Alimova M, et al. Lenalidomide targets clonogenic side population in multiple myeloma: pathophysiologic and clinical implications. Blood. 2011;117(17):4409-4419.
32. Fikaris AJ, Lewis AE, Abulaiti A, Tsygankova OM, Meinkoth JL. Ras triggers ataxia-telangiectasia-mutated and Rad-3-related activation and apoptosis through sustained mitogenic signaling. J Biol Chem. 2006;281(46):34759-34767. (Pubitemid 46043245)
33. Wang E. Rapid disappearance of statin, a non-proliferating and senescent cell-specific protein, upon reentering the process of cell cycling. J Cell Biol. 1985;101(5 Pt 1):1695-1701. (Pubitemid 16192141)
34. Yusuf I, Kharas MG, Chen J, et al. KLF4 is a FOXO target gene that suppresses B cell proliferation. Int Immunol. 2008;20(5):671-681. (Pubitemid 351619235)
35. Luo J, Solimini NL, Elledge SJ. Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009;136(5):823-837.
36. Murray AW. Creative blocks: cell-cycle checkpoints and feedback controls. Nature. 1992;359(6396):599-604.
37. Dai Y, Grant S. New insights into checkpoint kinase 1 in the DNA damage response signaling network. Clin Cancer Res. 2010;16(2):376-383.
38. Niida H, Katsuno Y, Banerjee B, Hande MP, Nakanishi M. Specific role of Chk1 phosphorylations in cell survival and checkpoint activation. Mol Cell Biol. 2007;27(7):2572-2581. (Pubitemid 46581348)
39. Enders GH. Expanded roles for Chk1 in genome maintenance. J Biol Chem. 2008;283(26):17749-17752.
40. Fuse E, Tanii H, Takai K, et al. Altered pharmacokinetics of a novel anticancer drug, UCN-01, caused by specific high affinity binding to alpha1-acid glycoprotein in humans. Cancer Res. 1999; 59(5):1054-1060. (Pubitemid 29135966)
41. Matthews DJ, Yakes FM, Chen J, et al. Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo. Cell Cycle. 2007;6(1):104-110. (Pubitemid 46173886)
42. Liu X, Yan S, Zhou T, Terada Y, Erikson RL. The MAP kinase pathway is required for entry into mitosis and cell survival. Oncogene. 2004;23(3):763-776. (Pubitemid 38241277)
43. Chung EJ, Brown AP, Asano H, et al. In vitro and in vivo radiosensitization with AZD6244 (ARRY-142886), an inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2 kinase. Clin Cancer Res. 2009;15(9):3050-3057.
44. Mogila V, Xia F, Li WX. An intrinsic cell cycle checkpoint pathway mediated by MEK and ERK in Drosophila. Dev Cell. 2006;11(4):575-582. (Pubitemid 44430898)
45. Ewings KE, Hadfield-Moorhouse K, Wiggins CM, et al. ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. 2007;26(12):2856-2867. (Pubitemid 46975775)
46. Goudelock DM, Jiang K, Pereira E, Russell B, Sanchez Y. Regulatory interactions between the checkpoint kinase Chk1 and the proteins of the DNA-dependent protein kinase complex. J Biol Chem. 2003;278(32):29940-29947. (Pubitemid 36962382)
47. Yacoub A, Park JS, Qiao L, Dent P, Hagan MP. MAPK dependence of DNA damage repair: ionizing radiation and the induction of expression of the DNA repair genes XRCC1 and ERCC1 in DU145 human prostate carcinoma cells in a MEK1/2 dependent fashion. Int J Radiat Biol. 2001;77(10):1067-1078. (Pubitemid 32977935)
48. Branzei D, Foiani M. Regulation of DNA repair throughout the cell cycle. Nat Rev Mol Cell Biol. 2008;9(4):297-308. (Pubitemid 351430844)
49. Golding SE, Rosenberg E, Neill S, et al. Extracellular signal-related kinase positively regulates ataxia telangiectasia mutated, homologous recombination repair, and the DNA damage response. Cancer Res. 2007;67(3):1046-1053.
50. Sørensen CS, Hansen LT, Dziegielewski J, et al. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 2005;7(2):195-201. (Pubitemid 40268135)